Insmed Incorporated

Insmed Incorporated is a global biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. Its current portfolio includes an approved treatment for Mycobacterium avium complex lung disease, along with clinical-stage programs focused on pulmonary and inflammatory conditions. The company’s pipeline emphasizes innovative approaches such as oral therapies and inhaled medicines designed to address difficult-to-treat respiratory disorders. Insmed also conducts research across multiple scientific platforms, including protein engineering and other advanced drug-development technologies. Headquartered in Bridgewater, New Jersey, Insmed serves patients and healthcare providers in the United States, Europe, Japan, and other international markets, positioning itself as a specialist in rare-disease and specialty respiratory treatment.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. William H. Lewis J.D., M.B.A.

Employees

1,664

Headquarters

Bridgewater, NJ, United States

Website

www.insmed.com